A
Ascendis Pharma
Long-acting prodrug therapies for rare endocrine diseases
At a glance
- Status
- Listed
- Listing
- IPO 2015
Open roles
Ascendis Pharma in the Gentofte Municipality ecosystem
The Ascendis Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Sofinnova Partners- GHGilde Healthcare
Series B and later6 investors entered at this stage
- RCRock Springs Capital
OrbiMed
RA Capital Management
Vivo Capital- SISofinnova Investments
Venrock
Source: Dealroom Talent Intelligence.
Patents
112 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Ascendis Pharma was the backer or acquirer, 2018–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
3 deals across Ascendis Pharma's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where Ascendis Pharma deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
Ascendis Pharma's portfolio, mapped.
See Ascendis Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
EMA panel backs Ascendis Pharma's weekly growth drug YUVIWEL for achondroplasia in Europe
Novo Nordisk ends $285M TransCon partnership with Ascendis, which will now develop monthly obesity drug itself
